XTL Biopharmaceuticals Ltd. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported operating loss of $466,000 against $481,000 a year ago. Loss from continuing operations was $477,000 or $0.002 per basic and diluted share against $427,000 or $0.001 per basic and diluted share a year ago. Loss attributable to equity holders of the company was $477,000 or $0.002 per basic and diluted share against $427,000 or $0.001 per basic and diluted share a year ago. For the six months, the company reported operating loss of $1,068,000 against $857,000 a year ago. Loss from continuing operations was $1,054,000 or $0.004 per basic and diluted share against $1,043,000 or $0.004 per basic and diluted share a year ago. Loss attributable to equity holders of the company was $1,054,000 or $0.004 per basic and diluted share against $1,505,000 or $0.006 per basic and diluted share a year ago.